Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin L Jones

Showing results (291-300 of 393) with videos related to

Pageof 40
Sort By:
Cancer Immunology Research|June 8, 2019
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical TrialShihong Zhang, Karan Kohli, R Graeme Black, et al.
Gynecologic Oncology|June 28, 2017
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trialMartee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysisKay Savage, Maryou B K Lambros, David Robertson, et al.
Eclinicalmedicine|October 28, 2025
Health-related quality of life in patients with advanced soft tissue sarcoma receiving first-line palliative chemotherapy (HOLISTIC): longitudinal results from a prospective, observational cohort studyEvelyne Roets, Eugenie Younger, Robin L Jones, et al.
The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.
Cancers|February 15, 2022
Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type FibromatosisAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.
Cancers|June 24, 2022
Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor OutcomesAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.
Journal of Proteomics|April 25, 2021
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometryMartina Milighetti, Lukas Krasny, Alex T J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumourSuzanne George, Ping Chi, Michael C Heinrich, et al.
Pageof 40

Showing results (291-300 of 393) with videos related to

Sort By:
Pageof 40
Cancer Immunology Research|June 8, 2019
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical TrialShihong Zhang, Karan Kohli, R Graeme Black, et al.
Gynecologic Oncology|June 28, 2017
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trialMartee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysisKay Savage, Maryou B K Lambros, David Robertson, et al.
Eclinicalmedicine|October 28, 2025
Health-related quality of life in patients with advanced soft tissue sarcoma receiving first-line palliative chemotherapy (HOLISTIC): longitudinal results from a prospective, observational cohort studyEvelyne Roets, Eugenie Younger, Robin L Jones, et al.
The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.
Cancers|February 15, 2022
Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type FibromatosisAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.
Cancers|June 24, 2022
Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor OutcomesAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.
Journal of Proteomics|April 25, 2021
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometryMartina Milighetti, Lukas Krasny, Alex T J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumourSuzanne George, Ping Chi, Michael C Heinrich, et al.
Pageof 40